CJC-1295 DAC vs No DAC: What’s the Difference?

For research purposes only. Not for human or veterinary use.

CJC-1295 with DAC and the compound commonly called CJC-1295 without DAC differ in structure, albumin binding and signalling duration. This guide explains the research distinction.

1. Introduction

In the field of synthetic peptide research, few compounds generate as much nomenclature confusion as CJC-1295. Investigators exploring the growth hormone-releasing hormone (GHRH) axis frequently encounter two distinct compounds: CJC-1295 with DAC and CJC-1295 without DAC. Understanding the structural and functional differences between these two molecules is critical for selecting the appropriate compound for experimental models. This guide examines the structural characteristics, bioconjugation mechanisms, and analytical verification methods relevant to these research peptide categories.

2. What Is CJC-1295?

In scientific literature, the term CJC-1295 refers specifically to a synthetic analogue of human growth hormone-releasing factor, hGRF(1-29), that has been modified to extend its presence in plasma. Developed to overcome the short half-life of natural GHRH, CJC-1295 incorporates specific amino-acid substitutions designed to improve protease resistance, alongside a crucial structural addition: a maleimido group at the C-terminus. This specific modification allows the peptide to bioconjugate with endogenous albumin in vivo, which primarily serves to reduce renal clearance and enzymatic degradation. Studies have demonstrated that this CJC-1295 with DAC complex can remain in circulation beyond 72 hours in animal models, leading to prolonged receptor activation on the anterior pituitary [1].

3. What Does DAC Mean?

DAC stands for Drug Affinity Complex. In the context of CJC-1295, the DAC modification is an N-epsilon-3-maleimidopropionamide derivative attached to a lysine residue at the C-terminus of the peptide sequence. The maleimido group is highly reactive with free thiol groups, specifically the single free cysteine residue (Cys34) found on serum albumin. When introduced into a biological system, the DAC component forms a stable covalent bond with albumin. This bioconjugation process significantly increases the molecular weight of the circulating complex. By binding to this abundant transport protein, the active peptide sequence is shielded from rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV) and its renal clearance is profoundly delayed [1].

4. What Is Commonly Called CJC-1295 Without DAC?

The compound frequently sold commercially as CJC-1295 without DAC is scientifically identified as modified GRF(1-29). This is a common commercial label, and researchers must verify the exact sequence before initiating experiments. This peptide shares the same four amino-acid substitutions as true CJC-1295—which improve protease resistance—but lacks the crucial maleimido group (the DAC) at the C-terminus. Because it cannot bind to albumin, modified GRF(1-29) exhibits a shorter duration of action compared to its DAC-containing counterpart. The nomenclature “CJC-1295 without DAC” is a commercial misnomer that has persisted in the industry, despite the compound lacking the specific structural modification that defines the CJC-1295 molecule in scientific literature. Understanding this distinction is vital for maintaining accuracy in research documentation and experimental protocol design.

5. CJC-1295 DAC vs No DAC: Comparison Table

6. How Albumin Binding Changes Research Duration

The presence or absence of the DAC modification fundamentally alters the pharmacokinetic profile of the peptide in experimental models. Research involving human subjects has demonstrated that a single administration of CJC-1295 (with DAC) can result in dose-dependent increases in mean plasma growth hormone concentrations for six days or more, with an estimated half-life of 5.8 to 8.1 days [2]. In contrast, modified GRF(1-29) (without DAC) produces a shorter signalling duration. Neither version is inherently superior; rather, the suitability of each compound depends entirely on the specific requirements of the experimental model. Researchers studying sustained pathway activation typically select the DAC version for prolonged-exposure models, while those investigating rapid physiological responses often prefer the non-DAC variant for short-duration exposure models. In certain experimental designs, the non-DAC version is investigated alongside other compounds in a CJC-1295 No DAC + Ipamorelin Blend for specific research applications.

7. Why the Naming Causes Confusion

The persistence of the name “CJC-1295 without DAC” in commercial settings creates significant challenges for researchers attempting to align their experimental protocols with published literature. When reviewing scientific databases, searches for “CJC-1295” almost exclusively return studies characterising the albumin-binding, long-acting compound. Researchers must carefully verify the structural sequence of the compounds they procure to ensure experimental validity. Procuring compounds from suppliers that provide comprehensive structural data and transparent nomenclature is essential for maintaining rigorous laboratory standards. The conflation of these terms can lead to significant methodological errors if a short-acting compound is inadvertently utilised in a protocol designed for a long-acting bioconjugate.

8. Analytical Testing: Identity Versus Purity

Ensuring the correct compound is used in research requires robust analytical verification. Because the two peptides differ structurally by the presence of the DAC modification, their unconjugated forms exhibit distinct molecular masses. Reverse-phase HPLC can estimate chromatographic purity, while LC-MS supports identity by comparing the observed molecular mass with the expected value. Neither method alone proves the complete amino-acid sequence, content per vial, sterility or endotoxin status. Additional validated testing may be required. Researchers should always rely on comprehensive HPLC and mass spectrometry testing, alongside batch verification and COAs, to confirm the exact nature of their research materials before commencing experiments. This combined analytical approach helps establish whether the material is consistent with the expected compound.

9. Storage and Laboratory Handling

Proper storage is critical to maintaining the structural integrity of both forms of the peptide. Storage conditions should follow the supplier’s validated stability data and the requirements of the specific experimental protocol. In general, lyophilised peptides are sensitive to repeated freeze-thaw cycles, direct sunlight, and vigorous agitation, all of which may compromise sample integrity and the reactive maleimido group. Reconstitution diluents should be chosen based on the specific requirements of the laboratory assay. For comprehensive handling protocols, researchers should consult a detailed peptide storage guide.

10. Frequently Asked Questions

11. Conclusion

The distinction between CJC-1295 with DAC and modified GRF(1-29) (commonly called CJC-1295 without DAC) is a fundamental structural difference that dictates their behaviour in experimental models. By understanding the role of the Drug Affinity Complex in albumin bioconjugation and signalling duration, investigators can accurately select the appropriate compound for their specific research objectives. Precise nomenclature and rigorous analytical verification are indispensable for advancing scientific understanding in this complex field. Explore ZENTRA’s independently tested CJC-1295 research compounds, with batch-specific analytical reports and online COA verification, by visiting our research peptide catalogue.

Sources and References

1. [1] Jetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., & Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058. https://pubmed.ncbi.nlm.nih.gov/15817669/
2. [2] Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 91(3), 799–805. https://pubmed.ncbi.nlm.nih.gov/16352683/

For wider guidance on compound information, supplier checks and batch evidence, read our Research Peptides UK guide.

For research purposes only. Not for human or veterinary use.